CA/HDAC-IN-1
CA/HDAC-IN-1 (Compound 11) is a CA and HDAC inhibitor with Ki values of 7.4 nM, 31.0 nM, and 7.3 nM for hCA II, hCA IX, and hCA XII, respectively, and IC50 values of 0.21 μM and 3.60 μM for HDAC3 and HDAC8, respectively. CA/HDAC-IN-1 has anti-cancer activity against colon cancer, breast cancer, and melanoma.
For research use only. We do not sell to patients.
- Formula: C21H21N5O4S
- Molecular Weight:439.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
hCA II 7.4 nM (Ki) |
hCA XII 7.3 nM (Ki) |
HDAC3 0.21 μM (IC50) |
HDAC8 3.60 μM (IC50) |
hCA IX 31.0 nM (Ki) |
Chemical Information
-
Molecular Weight 439.49
-
Formula C21H21N5O4S
-
SMILES
O=C(NC1=CC=CC=C1N)C2=CC=C(CNC(NC3=CC=C(S(=O)(N)=O)C=C3)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CA/HDAC-IN-1 Related Classifications
HY-179271 Related Classifications
Powered by Bioz